| β | SE | Wald |
p-value
| HR | 95% CI |
---|
Genotype | 1.87 | 0.71 | 2.66 | < 0.05 | 6.52 | 1.64–25.99 |
Age (yrs) | −0.57 | 0.10 | −5.55 | < 0.05 | 0.57 | 0.46–0.69 |
Ambulatory Status | −3.01 | 0.79 | −3.84 | < 0.05 | 0.05 | 0.01–0.23 |
Corticosteroid-use (yrs) | −0.07 | 0.05 | −1.44 | 0.15 | 0.93 | 0.84–1.03 |
Weight (cm) | 0.02 | 0.01 | 2.29 | < 0.05 | 1.02 | 1.00–1.04 |
FVC (L) | −1.80 | 0.45 | −4.02 | < 0.05 | 0.17 | 0.07–0.39 |
- SE standard error, HR hazard ratio, CI confidence interval, FVC forced vital capacity, Age: patient age at entry into the study; Arg16: patients who were homozygous or heterozygous for the β2-adrenergic receptor (ADRB2) resulting in at least one arginine substitution at amino acid 16 (n = 26); Gly16: patients who were homozygous for ADRB2 resulting in a glycine substitution at amino acid 16 (n = 147); genotype was coded as: 0 = Arg16, 1 = Gly16; ambulatory status was coded as: 0 = non-ambulatory, 1 = ambulatory; there was a significant influence of genotype, ambulatory status, weight, and FVC on risk of NV use